Table 2.
Association between the iceA1 status and clinical outcomes
| Group/subgroup | OR (95% CI) | P-value | I2 (%) | Phet | Analysis model |
|---|---|---|---|---|---|
| Total | |||||
| PUD vs gastritis/NUD | 1.28 (1.03, 1.60) | 0.03 | 0 | 0.92 | FE |
| GC vs gastritis/NUD | 1.05 (0.78, 1.40) | 0.75 | 25 | 0.19 | FE |
| GC vs PUD | 0.88 (0.64, 1.19) | 0.40 | 3 | 0.42 | FE |
| People’s Republic of China | |||||
| PUD vs gastritis/NUD | 1.40 (1.07, 1.83) | 0.01 | 0 | 0.69 | FE |
| GC vs gastritis/NUD | 1.30 (0.89, 1.89) | 0.17 | 35 | 0.15 | FE |
| GC vs PUD | 0.85 (0.57, 1.26) | 0.42 | 34 | 0.15 | FE |
| Other countries | |||||
| PUD vs gastritis/NUD | 1.07 (0.73, 1.57) | 0.73 | 0 | 0.98 | FE |
| GC vs gastritis/NUD | 0.74 (0.46, 1.20) | 0.22 | 0 | 0.50 | FE |
| GC vs PUD | 0.92 (0.56, 1.49) | 0.73 | 0 | 0.34 | FE |
Abbreviations: PUD, peptic ulcer disease; NUD, nonulcer dyspepsia; GC, gastric carcinoma; OR, odds ratio; I2, I-squared; Phet, P-value for heterogeneity test; FE, fixed-effect model; CI, confidence interval.